Charting Dosage-Form Manufacturing - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Charting Dosage-Form Manufacturing
Contract manufacturers expand capabilities in aseptic processing, clinical-trial materials supply, and cytotoxic manufacturing.

Pharmaceutical Technology

Restructuring for some

As some companies make select expansions, other leading contract manufacturers are restructuring. At the end of last year, Patheon (Toronto, Ontario), a contract manufacturer of solids, semisolids, and liquid dosage forms, outlined its progress in returning to profitability. In December 2007, Patheon reported a modest gain in revenues from continuing operations for fiscal year 2007 (ended Oct. 31, 2007) to $677.1 million compared with $674.1 million in the year-ago period. Its loss from continuing operations for FY 2007 was $84.5 million compared with $288.7 million for FY 2006.

Contributing positively to its financial results were its European, Canadian, and Cincinnati sites, which generated revenues of $577.3 million in FY 2007, an increase of 6% over 2006, according to a company release. These gains, however, were offset by losses in the company's Puerto Rico facilities in the fourth quarter. The company was affected by generic competition and resulting significantly lower revenues in the fourth quarter for "Omnicef" (cefdinir), the largest single product manufactured at its Carolina site. Its Caguas facility also experienced increased losses because of lower revenues of several products and various operating efficiencies.

Patheon reported in December that it will retain and continue to streamline its facilities in Caguas and Manati. Patheon hopes to return its Puerto Rico operations to break-even on a EBITDA (earnings before interest, taxes, depreciation, and amortization) level by the end of FY 2008. To that end, Patheon reduced its workforce at Caguas by 40 to bring the total workforce at Caguas and Manati to 775 positions as of the end of fiscal 2007. It also secured commitments to manufacture four additional products and expects revenues for these products to begin contributing to its bottom line in 2008.

The company, however, plans to divest its 230,000-ft2 facility in Carolina, Puerto Rico. The Carolina site specializes in manufacturing oral cephalosporin solid-dosage forms, including tablets, capsules, and powders for suspension.

Patheon also is in the process of restructuring its Canadian operations. In December 2007, it agreed to sell its Niagara-Burlington OTC pharmaceutical manufacturing business to Pharmetics (Laval, Quebec), a nutraceuticals producer. The deal includes the assets of Patheon's facilities in Fort Erie and Burlington, Ontario. As of press time, the deal was scheduled to close by Jan. 31, 2008.

The divestment of its Niagara-Burlington OTC business is part of a larger strategy by Patheon to improve its profitability by focusing on manufacturing prescription pharmaceutical products. Patheon announced in April 2007 plans to restructure its six manufacturing facilities in Canada. In addition to divesting its Niagara-Burlington OTC business, Patheon plans to close its York Mills, Toronto, facility and transfer substantially all commercial production and development services to its site in Whitby, Ontario. The process of transferring production to other facilities is expected to be completed by the first half of fiscal year 2009.

Patricia Van Arnum is a senior editor at Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ, 08830, tel. 732.346.3072,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What impact do mega-mergers of biopharmaceutical companies have on the development of new drugs?
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Improves the quality and number of innovative drugs available to patients.
Restricts innovation and the development of new drugs.
Has no impact on drug development.
Do not know.
Eric Langer Outsourcing Outlook Eric LangerOutsourcing No Longer Just for Cost-Cutting
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerSeeking Alternative Catalyst Solutions
Jill Wechsler Regulatory Watch Jill Wechsler Global Expansion Shapes Drug Oversight
Chris Burgess Statistical Solutions Chris BurgessIs a Sample Size of n=6 a Magic Number?
Sean Milmo European Regulatory WatchSean MilmoRegulating the Environmental Impact of Pharmaceuticals
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Source: Pharmaceutical Technology,
Click here